vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Triumph Financial, Inc. (TFIN). Click either name above to swap in a different company.

Triumph Financial, Inc. is the larger business by last-quarter revenue ($120.1M vs $75.1M, roughly 1.6× MEDIFAST INC). On growth, Triumph Financial, Inc. posted the faster year-over-year revenue change (16.0% vs -36.9%). Over the past eight quarters, Triumph Financial, Inc.'s revenue compounded faster (9.0% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

The Triumph Motor Company was a British car and motor manufacturing company in the 19th and 20th centuries. The marque had its origins in 1885 when Siegfried Bettmann of Nuremberg formed S. Bettmann & Co. and started importing bicycles from Europe and selling them under his own trade name in London. The trade name became "Triumph" the following year, and in 1887 Bettmann was joined by a partner, Moritz Schulte, also from Germany. In 1889, the businessmen started producing their own bicycles i...

MED vs TFIN — Head-to-Head

Bigger by revenue
TFIN
TFIN
1.6× larger
TFIN
$120.1M
$75.1M
MED
Growing faster (revenue YoY)
TFIN
TFIN
+52.9% gap
TFIN
16.0%
-36.9%
MED
Faster 2-yr revenue CAGR
TFIN
TFIN
Annualised
TFIN
9.0%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
TFIN
TFIN
Revenue
$75.1M
$120.1M
Net Profit
Gross Margin
69.4%
Operating Margin
-10.4%
Net Margin
Revenue YoY
-36.9%
16.0%
Net Profit YoY
400.6%
EPS (diluted)
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
TFIN
TFIN
Q4 25
$75.1M
$120.1M
Q3 25
$89.4M
$109.3M
Q2 25
$105.6M
$108.1M
Q1 25
$115.7M
$101.6M
Q4 24
$119.0M
$103.6M
Q3 24
$140.2M
$106.2M
Q2 24
$168.6M
$105.1M
Q1 24
$174.7M
$101.0M
Net Profit
MED
MED
TFIN
TFIN
Q4 25
Q3 25
$-2.3M
$1.7M
Q2 25
$2.5M
$4.4M
Q1 25
$-772.0K
$17.0K
Q4 24
$3.8M
Q3 24
$1.1M
$5.3M
Q2 24
$-8.2M
$2.7M
Q1 24
$8.3M
$4.2M
Gross Margin
MED
MED
TFIN
TFIN
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
TFIN
TFIN
Q4 25
-10.4%
Q3 25
-4.6%
1.2%
Q2 25
-1.0%
7.3%
Q1 25
-1.1%
0.1%
Q4 24
0.6%
5.6%
Q3 24
1.5%
5.9%
Q2 24
-4.7%
3.4%
Q1 24
4.5%
4.7%
Net Margin
MED
MED
TFIN
TFIN
Q4 25
Q3 25
-2.5%
1.6%
Q2 25
2.3%
4.1%
Q1 25
-0.7%
0.0%
Q4 24
3.7%
Q3 24
0.8%
5.0%
Q2 24
-4.8%
2.6%
Q1 24
4.8%
4.1%
EPS (diluted)
MED
MED
TFIN
TFIN
Q4 25
$-1.64
Q3 25
$-0.21
$0.04
Q2 25
$0.22
$0.15
Q1 25
$-0.07
$-0.03
Q4 24
$0.08
$0.13
Q3 24
$0.10
$0.19
Q2 24
$-0.75
$0.08
Q1 24
$0.76
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
TFIN
TFIN
Cash + ST InvestmentsLiquidity on hand
$167.3M
$248.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$941.8M
Total Assets
$248.0M
$6.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
TFIN
TFIN
Q4 25
$167.3M
$248.5M
Q3 25
$173.5M
$147.2M
Q2 25
$162.7M
$282.3M
Q1 25
$164.6M
$502.9M
Q4 24
$162.3M
$330.1M
Q3 24
$170.0M
$489.3M
Q2 24
$163.5M
$500.7M
Q1 24
$156.4M
$417.0M
Stockholders' Equity
MED
MED
TFIN
TFIN
Q4 25
$198.9M
$941.8M
Q3 25
$214.7M
$919.3M
Q2 25
$216.0M
$912.4M
Q1 25
$211.0M
$893.9M
Q4 24
$210.1M
$890.9M
Q3 24
$207.3M
$885.8M
Q2 24
$205.3M
$874.2M
Q1 24
$211.0M
$872.3M
Total Assets
MED
MED
TFIN
TFIN
Q4 25
$248.0M
$6.4B
Q3 25
$268.2M
$6.4B
Q2 25
$269.3M
$6.5B
Q1 25
$280.0M
$6.3B
Q4 24
$284.2M
$5.9B
Q3 24
$291.2M
$5.9B
Q2 24
$293.5M
$5.8B
Q1 24
$302.8M
$5.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
TFIN
TFIN
Operating Cash FlowLast quarter
$-5.3M
$67.1M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
TFIN
TFIN
Q4 25
$-5.3M
$67.1M
Q3 25
$12.1M
$24.4M
Q2 25
$-3.4M
$9.8M
Q1 25
$3.4M
$-3.6M
Q4 24
$-4.9M
$58.5M
Q3 24
$9.1M
$26.6M
Q2 24
$13.1M
$21.9M
Q1 24
$7.3M
$-10.7M
Free Cash Flow
MED
MED
TFIN
TFIN
Q4 25
$-6.6M
Q3 25
$10.8M
$22.4M
Q2 25
$-4.8M
$6.8M
Q1 25
$1.9M
$-7.9M
Q4 24
$-7.2M
Q3 24
$7.7M
$25.8M
Q2 24
$11.1M
$-31.9M
Q1 24
$5.4M
FCF Margin
MED
MED
TFIN
TFIN
Q4 25
-8.8%
Q3 25
12.0%
20.5%
Q2 25
-4.5%
6.2%
Q1 25
1.6%
-7.7%
Q4 24
-6.1%
Q3 24
5.5%
24.3%
Q2 24
6.6%
-30.3%
Q1 24
3.1%
Capex Intensity
MED
MED
TFIN
TFIN
Q4 25
1.8%
Q3 25
1.5%
1.8%
Q2 25
1.3%
2.8%
Q1 25
1.3%
4.2%
Q4 24
1.9%
Q3 24
1.0%
0.8%
Q2 24
1.1%
51.1%
Q1 24
1.1%
Cash Conversion
MED
MED
TFIN
TFIN
Q4 25
Q3 25
14.29×
Q2 25
-1.36×
2.22×
Q1 25
-212.82×
Q4 24
15.25×
Q3 24
8.04×
4.97×
Q2 24
7.95×
Q1 24
0.88×
-2.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons